Whitney Cavanagh

Whitney Cavanagh has over 30 years of work experience in the pharmaceutical and biotech industry. Whitney has held various leadership roles throughout their career, including Vice President of Portfolio & Program Management at Brii Biosciences and Zenas BioPharma. Prior to that, they served as the Vice President of Program Management at Sio Gene Therapies from 2018 to 2021. Before joining Sio Gene Therapies, Whitney was the Head of Integrated Evidence Planning at UCB and the Head of Project Management at Chimerix, Inc. Whitney also held strategic positions at Stiefel, a GSK company, Apotex, Searle, Biovail Technologies, and Kos Pharmaceuticals. With their extensive experience in program management, portfolio planning, and project management, Whitney has a strong track record of driving successful outcomes in the industry.

Whitney Cavanagh earned a Bachelor of Science degree in Chemistry and Biology from Eastern Connecticut State University, where they studied from 1987 to 1991.